A novel system for active targeting of inflammatory lesions has been established. A SLex- CMPul conjugate (2) showed accumulation that was 2.5-fold higher in inflammatory lesions in vivo than a SLN-CMPul conjugate (4) and 300-fold higher than monovalent SLex (6).